| CHD |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$0.900 vs. cons $0.894 |
MEDIUM |
| CHD |
Report |
Organic sales growth |
MISS |
pred ~3.10% vs. cons 3.25% |
MEDIUM |
| CHD |
Report |
Net sales |
IN-LINE |
pred ~$1.498B vs. cons $1.503B |
MEDIUM |
| CHD |
Guide |
Q3 2026 adjusted EPS |
LOWER |
guide ~$0.920 vs. cons $0.932 |
LOW |
| CHD |
Guide |
FY 2026 organic sales growth |
UNCHANGED |
guide 3%-4% vs. cons 3.77% |
MEDIUM |
| CHD |
Guide |
FY 2026 adjusted EPS growth |
UNCHANGED |
guide 5%-8% vs. cons $3.753 |
MEDIUM |
| CHD |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| CHD |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — Q3 de-risking should drive estimate pressure |
LOW |